Skip to main content
Fig. 3 | BMC Gastroenterology

Fig. 3

From: Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

Fig. 3

A A comparison of infliximab versus vedolizumab for key efficacy outcomes in patients with Crohn’s disease. Abbreviation: CDAI, Crohn’s Disease Activity Index; IFX, infliximab; VDZ, vedolizumab. B A comparison of infliximab versus vedolizumab for key efficacy outcomes in patients with ulcerative colitis. Abbreviation: IFX, infliximab; VDZ, vedolizumab

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us